Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial Commentaries

Estrogen Replacement Therapy and Cardiac Function Under Metabolic Syndrome

A Treacherous Art

Aijun Sun, Jun Ren
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.111.186817
Hypertension. 2012;59:552-554
Originally published February 15, 2012
Aijun Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Ren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

See related article, pp 694–704

Regardless of age, race, and ethnicity, cardiovascular disease is the number 1 cause of death for women, and its prevalence rises rapidly after menopause.1–4 This postmenopausal increase is believed to result from the loss of endogenous estrogen. Although estrogen replacement therapy (ERT) has long been thought to protect against menopause-associated cardiovascular anomalies, osteoporosis, hot flashes, and thinning of the vaginal epithelium,3–5 findings from the Heart and Estrogen/Progestin Replacement Study and the Women's Health Initiative Study5 do not support the notion that ERT protects the cardiovascular system. Instead, the data indicate just the opposite, that is, increased risk of cardiovascular disease, in addition to the apparent higher risk of breast cancer and deep vein thrombosis.1,2,4

Although results from clinical trials have substantiated the beneficial role of ERT in the management of menopausal symptoms, the unexpected finding of exacerbated cardiovascular function after ERT has made women hesitant to initiate ERT after menopause.1 Further analysis of the clinical trials revealed that the age of a woman and especially the number of years after menopause onset may be primary factors that contribute to the ultimate cardiovascular outcome of ERT. Although estrogen-progesterone therapy was found beneficial in young postmenopausal women, it increased cardiovascular risk when initiated in older postmenopausal women with established coronary artery disease.2,4 It is, thus, recommended that ERT be limited to the shortest duration consistent with treatment goals (eg, relief of menopausal symptoms).1 In contrast to the generalized recommendation for short duration of menopausal hormone treatment,2,4 careful scrutiny of the data from the Women's Health Initiative Estrogen Plus Progestin Trial reveal a reduced coronary heart disease risk after 5 to 6 years of ERT treatment. Accordingly, the overall effect of ERT on cardiovascular health in postmenopausal women is controversial, making it difficult to evaluate individualized care based on the risk:benefit ratio.

A number of studies have reported a potential link between reduced estrogen and the prevalence of metabolic syndrome, a complex, debilitating disorder that includes hypertension, diabetes mellitus, and dyslipidemia.3 However, a reduced incidence of type 2 diabetes mellitus and obesity was noted in otherwise healthy postmenopausal women who received estrogen.3 This inverse correlation between estrogen and metabolic syndrome suggests that estrogen deficiency that accompanies menopause may play a role in the onset and development of metabolic syndrome. Thus, despite the controversies regarding ERT, it appears that younger postmenopausal women with metabolic syndrome may benefit from ERT. However, there are still major gaps in our knowledge base. The pathophysiology of metabolic syndrome in perimenopausal and postmenopausal women is still not well understood, although ambient reproductive hormone levels are believed not to be the only variables that affect the frequency and severity of metabolic syndrome in women. It is particularly worrisome that some studies have indicated a potential tie between severity of menopausal syndrome (eg, hot flashes) and increased cardiovascular risk,1,3 suggesting that younger postmenopausal women with metabolic syndrome who most need ERT for symptom relief may be at a greater risk of adverse effects from ERT.

In this issue of Hypertension, Murase et al6 examined the effect of ERT on obesity, cardiac geometry and contractile function using a new model of metabolic syndrome, the DahlS.Z-Leprfa/ Leprfa (DS/obese) rats derived from a cross between Dahl salt-sensitive and Zucker rats.6 Animals ovariectomized at 7 weeks of age received an estrogen pellet or placebo at 8 weeks. Age-matched female homozygous lean littermates (DahlS.Z-Lepr+/Lepr+ or DS/lean rats) of DS/obese rats served as controls. Ovx-DS/obese rats manifested hypertension at 7 weeks of age and thereafter and exhibited left ventricular fibrosis and diastolic dysfunction at 13 weeks of age. ERT attenuated hypertension in Ovx-DS/obese rats without affecting blood pressure in ovariectomized DS/lean (Ovx-DS/lean) rats. ERT exacerbated left ventricular fibrosis and diastolic dysfunction and further increased cardiac oxidative stress and inflammation in Ovx-DS/obese and Ovx-DS/lean rats. Consistent with the reported beneficial effect of estrogen on metabolic syndrome,3 ERT reduced food intake, body weight, and visceral fat content in both Ovx-DS/obese and Ovx-DS/lean rats. These authors concluded that ERT may attenuate hypertension and obesity but exacerbated cardiac fibrosis and diastolic dysfunction in Ovx-DS/obese rats. These latter effects are thought to be mediated through increased cardiac oxidative stress and inflammation.

Collectively these findings revealed a detrimental effect of ERT on cardiac remodeling and function despite a beneficial protective effect against hypertension and obesity in metabolic syndrome. These harmful sequelae of ERT in the setting of obesity are distinct from those found in volume-overloaded cardiac hypertrophy where ERT delays the progression of adverse cardiac remodeling and dysfunction in volume-overloaded, ovariectomized rats.7 Further examination revealed that ERT protects against cardiac hypertrophy and dysfunction through improved tissue inhibitors of metalloproteinase 2/matrix metalloproteinase 2 and tissue inhibitors of metalloproteinase 1/matrix metalloproteinase 9 protein balance, restored estrogen receptor-α expression, and prevented matrix metalloproteinase 9 activation and perivascular collagen accumulation. These findings support the notion that estrogen limits undesirable extracellular matrix remodeling and ventricular dilation in volume-overloaded hearts.8 Similarly, female mice were found resistant to deoxycorticosterone acetate-salt–induced cardiac hypertrophy through estrogen receptor–induced adaptive stress signaling activation and inhibition of maladaptive calcineurin signaling in deoxycorticosterone acetate–treated female mice.7 Therefore, ERT may exert distinctive effects under different physiological/pathological conditions.

Several lines of evidence indicate that estrogen protects the cardiovascular system through modulation of neuronal and endothelial isoforms of NO synthase (NOS).5,8 However, it is also evident that estrogen may activate the renin-angiotensin-aldosterone system (RAAS) and promote oxidative stress, which, in turn, may or may not depend on NOS and lead to cardiac injury.5,9 Although the current study did not provide precise mechanism(s) of action behind ERT-induced disparate responses in blood pressure, obesity, and cardiac anomalies, it may be speculated that changes in cardiac NOS (in particular, neuronal NOS and endothelial NOS) may play a role in the enhanced oxidative stress and cardiac injury under metabolic syndrome. Both isoforms of NOS are heavily dependent on their cofactor tetrahydrobiopterin, the deficiency of which leads to NOS uncoupling and generation of superoxide rather than NO. Superoxide plays a key role in metabolic syndrome and aging-related increased cardiac anomalies because of its oxidative potential and ability to further reduce NO bioavailability. Loss of estrogen after ovariectomy results in myocardial deficiency of tetrahydrobiopterin in mRen2.Lewis rats, leading to diastolic dysfunction, adverse left ventricular remodeling, increases in cardiac superoxide production, and reduced cardiac NO release. With the exception of elevated heart weight induced by ovariectomy, other adverse changes were reversed by tetrahydrobiopterin supplementation. These observations are consistent with the finding that NOS serves as a key source of estrogen-stimulated superoxide production en route to deleterious cardiovascular effects of estrogen.5 Therefore, the state of NOS coupling/uncoupling may be pivotal in directing estrogen-induced cardiovascular effects, which may underline ERT-induced disparate responses in various pathological conditions, such as obesity and volume overload. In addition, chronic exposure to low levels of estrogen has been shown to increase superoxide levels in the rostral ventrolateral medulla, leading to hypertension. Although postmenopausal women have a higher cardiovascular risk that may be related to aging-induced NOS uncoupling,5,10 additional studies are needed before this potential cause-and-effect relationship can be consolidated. A schematic diagram is provided to illustrate the main mechanisms discussed (Figure).

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Schematic diagram depicting cardiovascular benefits vs risks of estrogen. Under physiological condition, NO synthase (NOS) is coupled to allow estrogen to generate the cardiovascular protective NO. However, under pathological conditions such as diabetes mellitus, obesity, and aging, NOS becomes uncoupled because of loss of tetrahydrobiopterin (BH4). With uncoupled NOS, estrogen promotes production of superoxide and reactive oxygen species (ROS). Estrogen is capable of activating the renin-angiotensin-aldosterone system (RAAS) to generate superoxide and ROS independent of NOS. NO and superoxide react to generate peroxynitrite (ONOO−). The increased superoxide, ROS, and ONOO−, as well as reduced bioavailability of NO, contribute to the cardiovascular abnormalities.

It is noteworthy that the rodent ovariectomized model does not precisely mimic naturally occurring menopause in women. However, the phenotypic characteristics in rodents after depletion of ovarian hormones, including left ventricular hypertrophy and hypertension, are similar to the pathophysiological changes occurring in postmenopausal women. Nonetheless, caution has to be taken when extrapolating information derived from animal studies.

Last but not least, the development of selective estrogen receptor modulators has shown promise in minimizing the cardiovascular risk of estrogen. Selective estrogen receptor modulators generate ligand receptor complexes with a 3D conformation capable of activating cell functions, with a profile distinct from estrogen. Analysis from Multiple Outcomes of Raloxifene Evaluation and Continuing Outcomes Relevant to Evista trials have depicted little difference in the incidence of serious cardiovascular events, stroke, uterine cancer, endometrial hyperplasia, ovarian cancer, or postmenopausal bleeding between the raloxifene and placebo groups.11 These observations suggest that specific agonistic actions of some selective estrogen receptor modulators are capable of circumventing the adverse effects associated with estrogen. To optimize the beneficial effect of ERT for individual patients, new research is urgently needed to evaluate the cardiovascular effect of selective estrogen receptor modulators, as well as the influence of time, duration, dose, route of administration, and agents on ERT-related risks and benefits in patients with metabolic syndrome.11

Disclosures

None.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

  • © 2012 American Heart Association, Inc.

References

  1. 1.↵
    1. Bittner V
    . Postmenopausal hormone therapy and the risk of cardiovascular disease. Expert Opin Pharmacother. 2009;10:2041–2053.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Harman SM,
    2. Vittinghoff E,
    3. Brinton EA,
    4. Budoff MJ,
    5. Cedars MI,
    6. Lobo RA,
    7. Merriam GR,
    8. Miller VM,
    9. Naftolin F,
    10. Pal L,
    11. Santoro N,
    12. Taylor HS,
    13. Black DM
    . Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011;124:199–205.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ren J,
    2. Kelley RO
    . Cardiac health in women with metabolic syndrome: Clinical aspects and pathophysiology. Obesity (Silver Spring). 2009;17:1114–1123.
    OpenUrlPubMed
  4. 4.↵
    1. Stefanick ML
    . Postmenopausal hormone therapy and cardiovascular disease in women. Nutr Metab Cardiovasc Dis. 2010;20:451–458.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. White RE,
    2. Gerrity R,
    3. Barman SA,
    4. Han G
    . Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women. Steroids. 2010;75:788–793.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Murase T,
    2. Hattori T,
    3. Ohtake M,
    4. Nakashima C,
    5. Takatsu M,
    6. Murohara T,
    7. Nagata K
    . Effects of estrogen on cardiovascular injury in ovariectomized female DahlS.Z-Leprfa/Leprfa rats as a new animal model of metabolic syndrome. Hypertension. 2012;59:694–704.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gurgen D,
    2. Hegner B,
    3. Kusch A,
    4. Catar R,
    5. Chaykovska L,
    6. Hoff U,
    7. Gross V,
    8. Slowinski T,
    9. da Costa Goncalves AC,
    10. Kintscher U,
    11. Gustafsson JA,
    12. Luft FC,
    13. Dragun D
    . Estrogen receptor-β signals left ventricular hypertrophy sex differences in normotensive deoxycorticosterone acetate-salt mice. Hypertension. 2011;57:648–654.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Voloshenyuk TG,
    2. Gardner JD
    . Estrogen improves timp-mmp balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Am J Physiol Regul Integr Comp Physiol. 2010;299:R683–R693.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Oestreicher EM,
    2. Guo C,
    3. Seely EW,
    4. Kikuchi T,
    5. Martinez-Vasquez D,
    6. Jonasson L,
    7. Yao T,
    8. Burr D,
    9. Mayoral S,
    10. Roubsanthisuk W,
    11. Ricchiuti V,
    12. Adler GK
    . Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-name and angiotensin II. Kidney Int. 2006;70:1759–1768.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Stice JP,
    2. Chen L,
    3. Kim SC,
    4. Jung JS,
    5. Tran AL,
    6. Liu TT,
    7. Knowlton AA
    . 17β-Estradiol, aging, inflammation, and the stress response in the female heart. Endocrinology. 2011;152:1589–1598.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Nilsson S,
    2. Koehler KF,
    3. Gustafsson JÅ
    . Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov. 2011;10:778–792.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
March 2012, Volume 59, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Estrogen Replacement Therapy and Cardiac Function Under Metabolic Syndrome
    Aijun Sun and Jun Ren
    Hypertension. 2012;59:552-554, originally published February 15, 2012
    https://doi.org/10.1161/HYPERTENSIONAHA.111.186817

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Estrogen Replacement Therapy and Cardiac Function Under Metabolic Syndrome
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Estrogen Replacement Therapy and Cardiac Function Under Metabolic Syndrome
    Aijun Sun and Jun Ren
    Hypertension. 2012;59:552-554, originally published February 15, 2012
    https://doi.org/10.1161/HYPERTENSIONAHA.111.186817
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Epidemiology, Lifestyle, and Prevention
    • Obesity
    • Epidemiology
  • Heart Failure and Cardiac Disease
    • Heart Failure
    • Cardiomyopathy

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured